期刊文献+

钙通道阻滞剂对治疗老年高血压临床疗效探讨 被引量:3

Analysis of Clinical Effect of Calcium Channel Blocker on the Treatment of Senile Hypertension
下载PDF
导出
摘要 目的观察钙通道阻滞剂对治疗老年高血压临床疗效。方法收取该院140例老年高血压患者,收取时间在2016年7月—2017年3月,并将老年高血压患者分为两组,对照组(70例患者实施叶酸治疗),观察组(70例患者实施拜新同治疗),探讨两组老年高血压患者的治疗效果。结果观察组患者发生头痛有1例、颜面潮红有2例、下肢水肿有3例、不良反应发生率为8.57%低于对照组(P<0.05),观察组老年患者BUM(5.60±1.62)ng/mL、TC(6.02±1.27)ng/mL、TG(1.32±0.90)ng/mL、GLU指标(5.78±1.01)ng/mL优于对照组(P<0.05),观察组老年高血压患者治疗后的心脑血管病死亡率2.86%低于对照组(P<0.05)。结论钙通道阻滞剂对治疗老年高血压患者具有显著治疗效果,能缓解不良反应,改善BUM、TC、TG、GLU指标以及降低心脑血管病死亡率,值得应用。 Objective This paper tries to observe the effect of calcium channel blockers on treatment of senile hypertension patients. Methods 140 elderly patients with hypertension treated in this hospital from July 2016 to March 2017 were selected and divided into two groups, with 70 patients in each group. The control group received folic acid treatment, the observation group received adalat treatment, and the clinical effect of both groups was analyzed. Results 1case of headache, 2 case of facial flushing, 3 case of lower limb edema occurred, the incidence rate of adverse reaction was 8.57%, lower than that of the control group(P0.05), BUM of the observation group was(5.60±1.62)ng/mL, TC of(6.02±1.27)ng/mL, TG was(1.32±0.90)ng/mL, GLU index was(5.78±1.01)ng/mL, better than the control group(P0.05),cardiovascular disease mortality of the observation group after treatment was 2.86%, lower than that of the control group(P0.05). Conclusion Calcium channel blockers have significant therapeutic effects on elderly patients with hypertension; it can alleviate their adverse reactions, improve BUM, TC, TG, GLU indicators, and reduce the mortality of cardiovascular and cerebrovascular diseases. Therefore, it is worth application
作者 严奉先
出处 《系统医学》 2017年第12期47-49,共3页 Systems Medicine
关键词 钙通道阻滞剂 老年高血压 临床疗效 观察 Calcium channel blocker Elderly hypertension Clinical curative effect Observation
  • 相关文献

参考文献8

二级参考文献73

  • 1中国成人血脂异常防治指南制订联合委员会编著.中国成人血脂异常防治指南[M].北京:人民卫生出版社,2007.
  • 2van Bilsen M,van Nieuwenhoven FA,van der Vusse GJ. Metabolic remodelling of the failing heart:beneficial or detrimental[J].Cardio-vasc Res,2009,(03):420-428.
  • 3Ashrafian H,Frenneaux MP,Opie LH. Metabolic mechanisms in heart failure[J].{H}CIRCULATION,2007,(04):434-448.
  • 4Beer M,Seyfarth T,Sandstede J. Absolute concentrations of high energy phosphate metabolites in normal,hypertrophied,and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy[J].J Am Con Cardiol,2002,(07):1267-1274.
  • 5Jougasaki M. Cardiotrophin-1 in cardiovascular regulation[J].{H}Advances in Clinical Chemistry,2010.41-76.
  • 6González A,López B,Ravassa S. Cardiotrophin-1 in hyperten-sive heart disease[J].{H}ENDOCRINE,2012,(01):9-17.
  • 7Khan SQ,Kelly D,Quinn P. Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction[J].{H}Journal of Cardiac failure,2006,(08):635-640.
  • 8Lopez N,Diez J,Fortuno MA. Differential hypertrophic effects of Cardiotrophin-1 on adult cardiomyocytes from normotensive and spon-taneously hypertensive rats[J].{H}Journal of Molecular and Cellular Cardiology,2006,(05):902-913.
  • 9Jougasaki M,Leskinen H,Larsen AM. Ventricular cardiotro-phin-1 activation precedes BNP in experimental heart failure[J].{H}PEPTIDES,2003,(06):889-892.
  • 10Mancia G,DeBacker G,Dominiczak A. 2007 Guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the european society of hypertension (ESH)and of the european society of cardiology (ESC)[J].J Eur Heart J,2007,(12):1462-1536.

共引文献292

同被引文献24

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部